Premium
Systematic review: hepatitis‐associated aplastic anaemia – a syndrome associated with abnormal immunological function
Author(s) -
GONZALEZCASAS R.,
GARCIABUEY L.,
JONES E. A.,
GISBERT J. P.,
MORENOOTERO R.
Publication year - 2009
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2009.04060.x
Subject(s) - medicine , aplastic anemia , immunology , hepatitis , hepatitis c , fulminant hepatitis , bone marrow failure , pure red cell aplasia , viral hepatitis , hepatitis b , transplantation , bone marrow , haematopoiesis , stem cell , biology , genetics
Summary Background Hepatitis‐associated aplastic anaemia is a syndrome in which marrow failure follows the development of hepatitis. Aim To review systematically the aetiology, immunopathogenesis, clinical presentation, diagnosis and treatment of hepatitis‐associated aplastic anaemia. Methods Literature searches were undertaken on the MEDLINE electronic database up to December 2008. Twenty‐four relevant studies were identified. The clinical and laboratory characteristics of the patients were analysed and reviewed. Results Hepatitis‐associated aplastic anemia is a variant of acquired aplastic anemia in which an episode of hepatitis precedes the onset of aplastic anemia. The hepatitis may be acute and severe, even fulminant; it may be self‐limiting or chronic. The pathology is often not attributable to a recognized cause of viral hepatitis. The syndrome occurs in 28 percent of young adults after liver transplantation for non‐A, non‐B, non‐C hepatitis. Several features of the syndrome suggest that the marrow aplasia is mediated by immunological mechanisms, possibly mediated by gamma interferon or the cytokine cascade. Survival of patients treated with hematopoietic cell transplantation has been 82%, and the response rate to immunosuppressive therapy 70%. Conclusions Hepatitis‐associated bone marrow aplasia is mediated by immunological mechanisms. Treatment options include hematopoietic cell transplantation and immunosuppressive therapy.